Birch cluster immunotherapy - Immunotek/ROXALL Medizin
Alternative Names: CLUSTOID BirkeLatest Information Update: 11 Apr 2023
At a glance
- Originator Immunotek SL
- Developer ROXALL Medizin GmbH
- Class Allergens; Allergy immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Allergic rhinoconjunctivitis
Most Recent Events
- 06 Apr 2023 Phase-II/III clinical trials in Allergic rhinoconjunctivitis in Germany (SC) (EudraCT2022-001587-97)
- 27 Jul 2022 Phase II development is ongoing in Germany (EudraCT2011-002296-42)
- 28 Oct 2019 Phase-II clinical trials in Allergic rhinoconjunctivitis in Germany (SC, Injection) (EudraCT2011-002296-42)